公开(公告)号：EP1687640A2

公开(公告)日：2006-08-09

申请号：EP05739600.4

申请日：2005-05-18

申请人： Kobenhavns Universitet ,  Statens Serum Institut ,  Harold Wood Lane Hospital

发明人： WEWER, Ulla M. ,  CHRISTIANSEN, Michael ,  FRÖLICH, Camilla ,  LAIGAARD, Jennie ,  NØRGAARD-PEDERSEN, Bent. ,  SPENCER, Kevin

IPC分类号： G01N33/68 ,  C12Q1/68

CPC分类号： G01N33/689 ,  G01N2333/4745 ,  G01N2333/96486 ,  G01N2800/36 ,  G01N2800/368 ,  G01N2800/385 ,  G01N2800/387 ,  Y10T436/143333

摘要： The present invention provides a method, an assay and a kit for proving an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum.